Home › Steatotic Liver Disease
Steatotic Liver Disease clinical trials recruiting in the U.S.
61 studies for Steatotic Liver Disease are recruiting participants at sites across the United States.
Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Learn about the causes and treatments.
Cities with the most studies
- Miami, FL17 studies
- San Antonio, TX16 studies
- New York City, NY16 studies
- Houston, TX14 studies
- Austin, TX13 studies
- San Diego, CA12 studies
- Hialeah, FL11 studies
- Richmond, VA11 studies
- New Orleans, LA10 studies
- Orlando, FL10 studies
- Tucson, AZ10 studies
- Cape Coral, FL9 studies
- Dallas, TX9 studies
- Chandler, AZ9 studies
- Dayton, OH8 studies
- Topeka, KS8 studies
- Waco, TX8 studies
- Ocala, FL8 studies
- Los Angeles, CA8 studies
- St. Louis, MO8 studies
- Pasadena, CA8 studies
- Round Rock, TX8 studies
- Durham, NC8 studies
- Little Rock, AR8 studies
- Parma, OH8 studies
- Brownsville, TX7 studies
- Sugar Land, TX7 studies
- Seattle, WA7 studies
- Doral, FL7 studies
- Akron, OH7 studies
- Rochester, MN7 studies
- Arlington, TX7 studies
- Washington, DC7 studies
- Las Vegas, NV7 studies
- Sandy Springs, GA7 studies
- Havelock, NC6 studies
- Sarasota, FL6 studies
- Homestead, FL6 studies
- Indianapolis, IN6 studies
- Fayetteville, NC6 studies
By state
- Alabama4 studies
- Arizona14 studies
- Arkansas8 studies
- California21 studies
- Colorado5 studies
- Connecticut5 studies
- Florida21 studies
- Georgia8 studies
- Illinois7 studies
- Indiana8 studies
- Iowa4 studies
- Kansas8 studies
- Kentucky4 studies
- Louisiana12 studies
- Maryland8 studies
- Massachusetts9 studies
- Michigan8 studies
- Minnesota8 studies
- Mississippi4 studies
- Missouri13 studies
- Nevada7 studies
- New Jersey6 studies
- New Mexico3 studies
- New York17 studies
- North Carolina14 studies
- Ohio15 studies
- Pennsylvania5 studies
- Rhode Island3 studies
- South Carolina5 studies
- Tennessee9 studies
- Texas20 studies
- Utah7 studies
- Virginia15 studies
- Washington7 studies
Recently updated studies
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Nov 13, 2026 · NCT06613698A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Nov 12, 2026 · NCT06528314Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Nov 9, 2026 · NCT07631637A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Nov 9, 2026 · NCT07288138NAFLD Clinical Care Pathway
RecruitingHealthy volunteers welcome
Ages 18 to 80 · All sexes · Updated Nov 9, 2026 · NCT06671886Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 5, 2026 · NCT07854782A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Nov 5, 2026 · NCT06920043A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 5, 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 5, 2026 · NCT07701993A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Nov 5, 2026 · NCT07358546Early Tracking of Childhood Health Determinants (ETCHED) Study
RecruitingObservational studyHealthy volunteers welcome
1 Day – 99 Years · All sexes · Updated Nov 2, 2026 · NCT03481829Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 100 · All sexes · Updated Oct 27, 2026 · NCT03884075Evaluation of Non-Invasive Tests for Metabolic Liver Disease
RecruitingObservational study
Ages 18 to 75 · All sexes · Updated Oct 26, 2026 · NCT07122700A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 23, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Oct 23, 2026 · NCT06318169Blood Collection Biorepository for Liver Disease Research
RecruitingObservational studyHealthy volunteers welcome
Ages 7 and older · All sexes · Updated Oct 8, 2026 · NCT03025074A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07165028A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07527910Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 28, 2026 · NCT05832229Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
RecruitingPhase 2
Ages 5 to 16 · All sexes · Updated Sep 22, 2026 · NCT06133101A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 17, 2026 · NCT07221188Human Models of Selective Insulin Resistance: Alpelisib, Part I
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Aug 24, 2026 · NCT06354088InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Aug 17, 2026 · NCT05463796Quantifying Hepatic Mitochondrial Fluxes in Humans
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT05305287Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
RecruitingHealthy volunteers welcome
Ages 25 to 55 · All sexes · Updated Aug 12, 2026 · NCT06993454From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.